Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.92 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.72 |
| ▸ | NQO2 | P16083 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8961276 | 0.98 | MTNR1A (0.92) | MTNR1AMTNR1BNQO2HTR2CALDH1A1 | |
| SCHEMBL8961097 | 0.97 | MTNR1A (0.90) | MTNR1AMTNR1BNQO2HTR2CALDH1A1 | |
| SCHEMBL8529185 | 0.96 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HTR2CALDH1A1 | |
| SCHEMBL8961075 | 0.91 | MTNR1A (0.79) | MTNR1AMTNR1BNQO2ALDH1A1KDM4E | |
| SCHEMBL8961069 | 0.90 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2ALDH1A1 | |
| SCHEMBL8961004 | 0.88 | MTNR1A (0.73) | MTNR1AMTNR1BNQO2ALDH1A1KDM4E | |
| SCHEMBL8961122 | 0.88 | MTNR1A (0.92) | MTNR1AMTNR1BNQO2HTR2CALDH1A1 | |
| SCHEMBL8960872 | 0.88 | MTNR1A (0.72) | MTNR1AMTNR1BNQO2HTR2CALDH1A1 | |
| SCHEMBL8961300 | 0.87 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2HTR2CALDH1A1 | |
| SCHEMBL8961253 | 0.87 | MTNR1A (0.84) | MTNR1AMTNR1BNQO2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5552418-A | FOR TREATING DISORDERS OF THE MELATONINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1996-09-03 | — | — | US | disclosed |